Effectiveness of penfluridol (oral long acting neuroleptic) as compared to second generation oral neuroleptics in psychotic disorder patients: an open label randomized controlled trial. - The One for Seven Study

Start Date23 Sep 2016

Sponsor / Collaborator

Erasmus University Rotterdam

100 Clinical Results associated with Penfluridol

100 Translational Medicine associated with Penfluridol

100 Patents (Medical) associated with Penfluridol

263

Literatures (Medical) associated with Penfluridol

29 Oct 2024·Nederlands tijdschrift voor geneeskunde

[Shortage antipsychotic medication supply hits vulnerable patients most].

Article

Author: Moerkens, S A ; TeStroet, Martijn A J ; Jacobsen, Bettina

Medication shortages in The Netherlands are getting worse since 2019, with numbers increasing every year. In September 2023, during our work in a psychiatric outpatient clinic, we were confronted with the consequences of these rising numbers. There was an acute shortage of penfluridol, an antipsychotic medication. Soon thereafter, another shortage occurred. The intramuscular depot of olanzapine (Zypadhera) was not available over a long period of time. Shortages of antipsychotic medication supply could have severe consequences. Stopping or switching medication can lead to psychotic decompensation. During a psychotic episode, a patient can lose his mental stability and all facets of life can be affected. Therefore, the medication shortages can have a life altering effect. As healthcare workers we feel obliged to report about the consequences of the severity of the rising number of medication shortages and highlight the consequences of the vulnerability of psychiatric patients.

01 Oct 2024·MedComm

Penfluridol inhibits melanoma growth and metastasis through enhancing von Hippel‒Lindau tumor suppressor‐mediated cancerous inhibitor of protein phosphatase 2A (CIP2A) degradation

Article

Author: Li, Jiao ; Xu, Fuyan ; Pu, Wenchen ; Ai, Min ; Qi, Yucheng ; Yang, Yang ; Ming, Yue ; Xia, Yong ; Sun, Qingxiang ; Zhang, Tingting ; Li, Cong ; Li, Zhang ; Yuan, Zhu ; Peng, Yong ; Xu, Xiaomin

AbstractMelanoma's high metastatic potential, especially to the brain, poses significant challenges to patient survival. The blood‒brain barrier (BBB) is a major obstacle to the effective treatment of melanoma brain metastases. We screened antipsychotic drugs capable of crossing the BBB and identified penfluridol (PF) as the most active candidate. PF reduced melanoma cell viability and induced apoptosis. In animal models, PF effectively inhibited melanoma growth and metastasis to the lung and brain. Using immunoprecipitation combined with high‐resolution mass spectrometry, and other techniques such as drug affinity responsive target stability, we identified CIP2A as a direct binding protein of PF. CIP2A is highly expressed in melanoma and its metastases, and is linked to poor prognosis. PF can restore Protein Phosphatase 2A activity by promoting CIP2A degradation, thereby inhibiting several key oncogenic pathways, including AKT and c‐Myc. Additionally, von Hippel‒Lindau (VHL) is the endogenous E3 ligase for CIP2A, and PF enhances the interaction between VHL and CIP2A, promoting the ubiquitin‒proteasome degradation of CIP2A, thereby inhibiting melanoma growth and metastasis. Overall, this study not only suggests PF's potential in treating melanoma and its brain metastases but also highlights CIP2A degradation as a therapeutic strategy for melanoma.

01 Aug 2024·Biomedicine & Pharmacotherapy

Penfluridol regulates p62 / Keap1 / Nrf2 signaling pathway to induce ferroptosis in osteosarcoma cells

Article

Author: Zheng, Jiyuan ; Sun, Naikun ; Zhang, Long ; Chen, Xiaohui ; Xiao, Keyi ; Zeng, Xianhui ; Lin, Guang-Xun ; Zeng, Xiangchen ; Rui, Gang ; Ren, Chong ; Luo, Zhong

The cure rate for patients with osteosarcoma (OS) has stagnated over the past few decades. Penfluridol, a first-generation antipsychotic, has demonstrated to prevent lung and esophageal malignancies from proliferation and metastasis. However, the effect of penfluridol on OS and its underlying molecular mechanism remains unclear. This study revealed that penfluridol effectively inhibited cell proliferation and migration, and induced G2/M phase arrest in OS cells. In addition, penfluridol treatment was found to increased reactive oxygen species (ROS) levels in OS cells. Combined with the RNA-Seq results, the anti-OS effect of penfluridol was hypothesized to be attributed to the induction of ferroptosis. Western blot results showed that penfluridol promoted intracellular Fe2+ concentration, membrane lipid peroxidation, and decreased intracellular GSH level to induce ferroptosis. Further studies showed that p62/Keap1/Nrf2 signaling pathway was implicated in penfluridol-induced ferroptosis in OS cells. Overexpression of p62 effectively reversed penfluridol-induced ferroptosis. In vivo, penfluridol effectively inhibited proliferation and prolonged survival in xenograft tumor model. Therefore, penfluridol is a promising drug targeting OS in the future.

100 Deals associated with Penfluridol

External Link

KEGG	Wiki	ATC	Drug Bank
D02630	Penfluridol	N05AG03	DB13791

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Schizophrenia	CN	Hunan Zhongnan Pharmaceutical Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2017	Not Applicable	Glioblastoma	-	Penfluridol	jyycewrrhl(udugefdpml) = mzreqjfwvv gloplkkbgv (wfnnayccog ) View more	-	01 Jul 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Penfluridol

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation